Lite Strategy, Inc. quarterly report, Q3 FY2018

Abrir documento

Filing identity and reporting period

Important discrepancy: The supplied filing is MEI Pharma, Inc.’s Form 10-Q for the quarter ended March 31, 2019, covering the three and nine months ended that date. It is not a Lite Strategy, Inc. filing or a 2017 Q3 filing.

MEI Pharma is a clinical-stage oncology company with four drug candidates: ME-401, voruciclib, ME-344 and pracinostat. Its revenue is from license and research-and-development arrangements, not reported product sales.

Financial results and liquidity

Amounts below are in millions of dollars unless otherwise stated.

  • Quarter revenue: $1.249, compared with $0.433 in the prior-year quarter. Quarter operating expenses were $13.865 and operating loss was $12.616, versus $6.487 and $6.054, respectively.
  • Quarter net loss: $17.355, versus $5.948; basic and diluted loss per share were $0.24, versus $0.16.
  • Nine-month revenue: $3.785, versus $1.074. Operating loss was $34.497, versus $21.113. Net loss was $19.872, versus $20.815; basic loss per share was $0.28, versus $0.56.
  • Costs and margins: Research and development expense was $9.071 for the quarter and $24.268 for nine months, up from $3.071 and $12.579. Cost of revenue was $1.163 and $3.161, respectively, against revenue of $1.249 and $3.785.
  • Cash and investments: $82.290 at March 31, 2019, including $7.426 cash and cash equivalents and $74.864 short-term U.S. government securities, down from $102.743 at June 30, 2018.
  • Cash flow: Operating activities used $21.359 in the first nine months, compared with $17.552 in the prior-year period. Investing activities provided $14.363 and financing activities provided $1.113. Cash and cash equivalents fell by $5.883 during the period.
  • Debt and liabilities: The filing does not report conventional borrowings. It reports a $31.971 warrant liability, down from $46.313, and total liabilities of $48.044. Current liabilities were $11.851; deferred revenue totaled $8.419, of which approximately $4.2 was expected to be recognized within 12 months.

Material changes and drivers

  • Revenue growth primarily reflects the October 2018 ME-401 license agreement with Kyowa Hakko Kirin (KHK), alongside continued recognition under the Helsinn pracinostat agreement. Nine-month revenue included $1.992 from KHK and $1.793 from Helsinn.
  • Research and development expense increased substantially, chiefly from ME-401 Phase 2 trial start-up, clinical-trial and manufacturing costs. General and administrative expense also rose, primarily due to increased headcount, share-based compensation and professional services.
  • The nine-month net loss includes a $13.274 noncash gain from remeasuring the warrant liability; the quarter included a $5.201 noncash loss. These fair-value changes materially affect comparisons of net loss. The nine-month diluted loss per share was $0.60, versus basic loss per share of $0.28; the filing’s diluted calculation includes warrant-related adjustments.
  • Shares outstanding rose from 70.406 million at June 30, 2018 to 71.281 million at March 31, 2019. Separately, 16.062 million warrants remained outstanding at March 31, 2019.

Outlook, risks and contingencies

  • Management expects operating losses and negative operating cash flow for the foreseeable future. It believed the $82.3 million of cash, cash equivalents and short-term investments would fund operations through at least fiscal 2020. Management also stated that future development may require financing, licensing or strategic partnerships.
  • ME-401 was in a randomized Phase 2 study in relapsed or refractory follicular lymphoma intended to support an accelerated-approval application; approval remains subject to FDA review. A clinical collaboration with BeiGene evaluates ME-401 with zanubrutinib, with study costs shared equally.
  • Pracinostat was in a Helsinn-funded Phase 3 AML trial and a Phase 2 MDS study. ME-344 and voruciclib remained in clinical development. Clinical outcomes and regulatory approvals are uncertain.
  • Key disclosed risks include financing needs, clinical-trial failure or delay, regulatory decisions, reliance on collaborators and third-party manufacturers, and potential milestone, royalty and other license obligations. Potential Presage and S*Bio milestone payments are not accrued; the S*Bio agreement includes up to $74.5 million in contingent milestones, while Presage includes up to $179 million in potential milestones.
  • The company reported no legal proceedings and no material changes to the risk factors in its 2018 annual report. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.

Investor verification priorities

  1. Confirm the filing identity and period: the source is MEI Pharma, Inc., quarter ended March 31, 2019, despite the request metadata.
  2. Assess cash runway against the reported $21.4 million nine-month operating cash use, planned clinical spending and management’s “through at least fiscal 2020” estimate.
  3. Review ME-401 Phase 2 progress, safety and efficacy data, and the FDA’s requirements for any accelerated-approval pathway.
  4. Separate operating performance from warrant-liability fair-value changes when interpreting net loss and diluted loss per share.
  5. Track potential dilution from outstanding warrants and equity awards, and contingent obligations under the Presage and S*Bio agreements.